Adam Laponis Sells 7,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 7,000 shares of the stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $50.00, for a total value of $350,000.00. Following the transaction, the chief financial officer owned 130,031 shares of the company’s stock, valued at $6,501,550. The trade was a 5.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Adam Laponis also recently made the following trade(s):

• On Tuesday, January 13th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $40.00, for a total value of $120,000.00.
• On Friday, January 9th, Adam Laponis sold 2,738 shares of Twist Bioscience stock. The stock was sold at an average price of $35.26, for a total transaction of $96,541.88.

Twist Bioscience Price Performance

TWST opened at $49.11 on Friday. The firm has a 50-day moving average price of $38.63 and a 200-day moving average price of $32.47. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $51.00. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -38.37 and a beta of 2.24.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. The firm’s revenue was up 16.9% on a year-over-year basis. Equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

TWST has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, February 3rd. Barclays boosted their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Finally, Evercore lifted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Quarry LP purchased a new stake in Twist Bioscience during the third quarter valued at about $28,000. Strategic Advocates LLC increased its position in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares in the last quarter. SBI Securities Co. Ltd. lifted its position in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after buying an additional 571 shares during the last quarter. Finally, Leonteq Securities AG purchased a new stake in Twist Bioscience in the fourth quarter worth approximately $48,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.